ReviewGut2014
Barrett's oesophagus: epidemiology, cancer risk and implications for management.
Review in Gut, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The relationship between metabolic syndrome and increased risk of Barrett's esophagus: an updated systematic review and meta-analysis.BMC gastroenterology · 2020Pooled it
- Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.Disease markers · 2019Pooled it
- Metabolic syndrome is associated with increased risk of Barrett esophagus: A meta-analysis.Medicine · 2016Pooled it
- The epidemiology, diagnosis, and treatment of Barrett's carcinoma.Deutsches Arzteblatt international · 2015Pooled it
- Trial
- Natural history of Barrett's esophagus over a 10-year period: a longitudinal endoscopic study in a Japanese population.Journal of gastroenterology · 2026Article
- Detection of high-grade dysplasia and adenocarcinoma in Barrett's esophagus using high-resolution virtual chromoendoscopy versus the Seattle protocol: the CONVERSE study.BMC gastroenterology · 2026Article
- A steadily increasing trend in the incidence of esophageal adenocarcinoma in Akita Prefecture, Japan, through 2024.Journal of gastroenterology · 2026Article
- Epidemiology of Risk Stratification, Machine Learning Early Prediction Model, and Tumor Suppressive Mechanism of RHBDF2 in Esophageal Cancer in Gansu Province.Cancer medicine · 2026Article
- Cancer risk by length of Barrett's esophagus in Japanese population: a nationwide multicenter retrospective cohort study.Journal of gastroenterology · 2024Article
- All-reflective tethered capsule endoscope for multimodal optical coherence tomography in the esophagus.Journal of biomedical optics · 2024Article
- Article
- Patients' values and preferences regarding endoscopic therapy for Barrett's esophagus: A cross-sectional survey study.DEN open · 2024Article
- Prevalence and associated factors of worry for cancer in patients with a Barrett's esophagus.Scientific reports · 2024Article
- The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review.Cancers · 2023Review
- Professionals' views on the justification for esophageal adenocarcinoma screening: A systematic literature search and qualitative analysis.Preventive medicine reports · 2023Review
- Augmented CPT1A Expression Is Associated with Proliferation and Colony Formation during Barrett's Tumorigenesis.International journal of molecular sciences · 2022Article
- Barrett Esophagus: Quality of life and factors associated with illness perception.United European gastroenterology journal · 2022Article
- Today's Mistakes and Tomorrow's Wisdom… In Barrett's Surveillance.Visceral medicine · 2022Review
- Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Although endoscopic surveillance of patients with Barrett's oesophagus has been widely implemented, its effectiveness is debateable. The recently reported low annual oesophageal adenocarcinoma risk in population studies, the failure to identify most Barrett's patients at risk of disease progression, the poor adherence to surveillance and biopsy protocols, and the significant risk of misclassification of dysplasia all tend to undermine the effectiveness of current management, in particular, endoscopic surveillance programmes, to prevent or improve the outcomes of patients with oesophageal adenocarcinoma. The ongoing increase in incidence of Barrett's oesophagus and consequent growth of the surveillance population, together with the associated discomfort and costs of endoscopic surveillance, demand improved techniques for accurately determining individual risk of oesophageal adenocarcinoma. More accurate techniques are needed to run efficient surveillance programmes in the coming decades. In this review, we will discuss the current knowledge on the epidemiology of Barrett's oesophagus, and the challenging epidemiological dilemmas that need to be addressed when assessing the current screening and surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.